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Background. Novel prognostic markers are needed so newly diagnosed breast cancer patients do not undergo any unnecessary
therapy. Various microarray gene expression datasets based studies have generated gene signatures to predict the prognosis
outcomes, while ignoring the large amount of information contained in established clinical markers. Nevertheless, small sample
sizes in individual microarray datasets remain a bottleneck in generating robust gene signatures that show limited predictive
power. The aim of this study is to achieve high classification accuracy for the good prognosis group and then achieve high
classification accuracy for the poor prognosis group.Methods. We propose a novel algorithm called the IPRE (integrated prognosis
risk estimation) algorithm. We used integrated microarray datasets from multiple studies to increase the sample sizes (∼2,700
samples). The IPRE algorithm consists of a virtual chromosome for the extraction of the prognostic gene signature that has 79
genes, and a multivariate logistic regression model that incorporates clinical data along with expression data to generate the risk
score formula that accurately categorizes breast cancer patients into two prognosis groups. Results. The evaluation on two testing
datasets showed that the IPRE algorithm achieved high classification accuracies of 82% and 87%, which was far greater than any
existing algorithms.
1. Introduction
The leading cause of death among breast cancer patients is
from distant metastasis and recurrence [1]. The early stage
prediction of prognosis after being diagnosed with breast
cancer remains one of the significant challenges in breast
cancer based clinical research. The accurate prediction of a
good prognosis (low risk) or poor prognosis (high risk) of
breast cancer patients based on metastasis or recurrence, can
administer the decision for appropriate therapy. Patients
categorized as low risk patients can be spared aggressive
therapies, for example, chemotherapy, and can be treated
with less toxic treatments, for example, tamoxifen or hor-
monal therapy. However, for patients categorized as high risk
patients, chemotherapy or a combination of chemotherapy
with other therapies may be the optimal therapy solution.
These adjuvant therapies have high medical costs and also
have vital short-term or long-term side effects [2]. Therefore,
accurate classification of two prognosis groups can increase
the survival rate of breast cancer patients and also reduce
unnecessary costs associated with treatment. This can be
achieved by developing robust prognostic tools that can
help clinicians accurately categorize the prognosis group
of patients and make effective and timely decisions about
available treatments.Therefore, a challenge is to extract novel
prognostic clinical or gene expression markers directly asso-
ciated with breast cancer that can accurately categorize the
two breast cancer prognosis groups.
During recent years, a wide number of disease markers
have been identified from microarray-based gene expres-
sion profiles that have shown great potential in predicting
the prognosis outcome for breast cancer [3–16]. Currently,
treatment guidelines such as the US National Institutes of
Health (NIH) [2] and St. Gallen [17] use clinical prognostic
factors such as lymph node status, tumour size, and histologic
grade in order to evaluate the distant metastasis risk for
breast cancer patients. In breast cancer, Mammaprint or a
70-gene marker (or signature) [3] and a 76-gene signature
[5], available commercially as a prognostic test [7], perform
well in predicting metastasis that opposes the performance
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of clinical criteria. Even though these guidelines and the
commercially available prognostic tests are popular, they are
incapable of accurately characterizing breast cancer patients
into high or low risk. As a result,many patients receive unnec-
essary adjuvant therapy, even when they can survive without
it. Due to these issues, various groups now aim for an effective
and robust gene expression signature that consists of genes
with prognostic biological significance.
The results from existing studies raise some key questions.
First, are the genes (from the gene signature) significantly
associated with breast cancer or their metastasis? Second,
if they are associated with breast cancer, are they cancer-
causing genes (since a genemay be associated with cancer but
not cause cancer)? Third, are the genes reproducible across
different datasets or heavily depended on the chosen training
set? Fourth, are the genes robust, providing similar classifica-
tion results on different testing datasets? Fifth, do the genes
represent the cancer related biological process GO terms
or the pathways associated with the cancers?
The DNA microarray technology generating microarray
gene expression datasets works as a robust tool in different
aspects of cancer based research.Themicroarray dataset con-
tains a low number of samples (∼100–200) with a very large
number of genes (∼10,000–40,000) used as the training set.
There is a greater chance of finding a gene signaturewith good
predictive power on the training set and heavily degrades
the performance on independent testing sets [9]. This is
known as an over-fitted gene signature as the number of
genes is far greater than the number of samples. Microarray
based breast cancer gene expression datasets usually consist
of a small number of samples due to the fact they are time
consuming and expensive, which has always been an issue for
accurately categorizing breast cancer prognosis groups [18].
Furthermore, at the time of predicting clinical outcomes, the
sample size is reduced even further due to missing clinical
factors for some of the samples in themicroarray dataset [19].
This problem can be greatly reduced by integrating multiple
microarray datasets from different studies that can increase
the sample size, possibly in the order of thousands.
Shen et al. [20] and Teschendorff et al. [21] used “meta-
analysis” to integrate different microarray datasets to develop
breast cancer based prognostic gene signatures [9]. However,
it is worthwhile noting that integrating microarray datasets
from different studies is not so simple due to the differ-
ent microarray platforms across different datasets, different
experimental protocols, and different preprocessing meth-
ods. Therefore, in order to resolve all of these issues and be
able to classify two prognosis groups of breast cancer patients
effectively, it is essential to develop a novel breast cancer
prognosis classifier that shows the good and stable classifi-
cation performance from independent datasets.
In this study, we focus on utilizing an integrated dataset
(that consists of a very large number of samples) along with
clinical data to improve the performance of breast cancer
prognosis classification. We define the two prognosis groups
as good prognosis, which corresponds to the breast cancer-
free state for at least 5 years, and the poor prognosis state,
which corresponds to the recurrence of breast cancer or
metastasis within 5 years. The prime goal of this study is to
achieve high classification accuracy for the good prognosis
group and then achieve high classification accuracy for the
poor prognosis group. To accomplish this aim, we propose
a breast cancer prognosis based classification algorithm by
developing a virtual chromosome (VC) consisting of two
components (correlation-factor and penalized-factor), which
are used to extract our prognostic gene signature that consists
of 79 genes.The extracted gene signature is then incorporated
into a multivariate logistic regression model along with
clinical variables for generating the risk score formula. A cut-
off score of −1.480 was then used to classify the samples as a
good-prognosis if the risk score was less than −1.480 and a
poor-prognosis if the risk score was greater than or equals
−1.480. We reported that when using the training dataset
consisting of an equal number of two prognosis groups, it
achieved a high classification performance in comparison to
the training dataset that consisted of an unequal ratio of the
two prognosis groups.The evaluation of our algorithm, called
integrated prognosis risk estimation (IPRE), and the exper-
imental comparisons with other prognosis based classifiers
demonstrated that the IPRE algorithm outperforms other
classifiers by achieving a high classification accuracy of 82%
(with specificity of 88%) and 87% (with specificity of 95%)
in the Desmedt [22] and the Vijver [3] datasets, respectively.
This illustrates the effectiveness of the IPRE algorithm. In
general, the IPRE algorithm achieves the following proper-
ties.
(i) High performance: achieves high classification per-
formance in terms of high accuracy (and high speci-
ficity) for classifying the two prognosis groups.
(ii) Dataset independence: achieves good results in the
independent testing datasets (i.e., the dataset that was
not used in the training dataset). This signifies the
independency of the IPRE algorithm for any testing
datasets or for any microarray platforms.
(iii) Better classification: able to outperform the accuracy
of seven other popular representative prognosis based
algorithms.
(iv) Biological significance: biological meaning of the
IPRE algorithm based prognostic gene signature is
significant and is related to the cancers.
2. Materials
Seventeen breast cancer microarray gene expression datasets
were downloaded from the publicly available NCBI GEO
database [12] or supporting website [13] that has multi-
ple platform types, that is, HG-U133A, HG-U133B, HG-
U133PLUS2.0, and theAgilentHumanGenome.Overlapping
samples or samples that have no clinical follow-up were
removed from the datasets. The remaining samples were
assigned either a high risk for metastasis/recurrence (if the
metastasis/recurrence was observed within 5 years of follow-
up) or low risk for metastasis/recurrence (if the metastasis/
recurrence was not observed within 5 years of follow-up).
The sample selection was independent of age, tumour grade,
or any other clinical parameters. We have used normalized
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Table 1: Breast cancer microarray gene expression datasets used in this study.
Data set Country Poor/good prognosis Samples Platform IHC References
GSE1456∗ Sweden 41/118 159 HG-U133A, HG-U133B NA [2]
GSE2990∗ Sweden, UK 37/85 189 HG-U133A ER [7]
GSE6532∗ Belgium 56/61, 100/150, 9/68 327, 255, 87 HG-U133A, HG-U133B, HG-U133Plus 2.0 ER, PR [11]
E-TABM-158∗ USA 54/63 118 HG-U133A ER, PR, HER2 [13]
GSE5327∗ USA 11/47 58 HG-U133A ER [17]
GSE2603∗ USA 36/46 121 HG-U133A ER, PR [18]
GSE31519∗ Germany 52/10 67 HG-U133A ER, PR, HER2 [22]
GSE3494∗ Sweden 60/176 251 HG-U133A, HG-U133B ER, PR [27]
GSE4922∗ Singapore 91/158 255 HG-U133A, HG-U133B ER [28]
GSE19615∗ USA 14/0 115 HG-U133Plus 2.0 ER, PR, HER2 [29]
GSE2034∗ Netherlands 106/180 286 HG-U133A ER [30]
GSE12276∗ Netherlands 190/14 204 HG-U133Plus 2.0 NA [31]
GSE11121∗ Germany 47/153 200 HG-U133A NA [32]
GSE7390§ Europe 44/154 198 HG-U133A ER [33]
van de Vijver§ Netherlands 84/211 295 Agilent Human Genome ER [34]
Total: 15 8 countries 1,042/1,694 3,185 4 platforms
∗Represents the training datasets and §represents the testing datasets.
microarray datasets (log
2
intensity for single-channel plat-
forms or log
2
ratio in dual channel platforms) as published
by the original studies.
2.1. Training and Testing Datasets. Thirteen microarray gene
expression datasets (see Table 1) were used as a training
dataset to extract the prognostic gene signature, and the
two microarray gene expression datasets, Desmedt dataset
(GSE7390) [22] and the Vijver dataset [3], were used as
a testing dataset for evaluating the performance of the
algorithm. These datasets were selected first on the basis of
metastasis or recurrence rate availability and then on tumour
size availability. For patient samples with a missing estrogen
receptor (ER) status and progesterone receptor (PR) status,
the dichotomized ER gene (ESR1) and PR gene (PgR) mRNA
(positive and negative) value was used instead. The probe
expressions of the datasets were then converted to gene
expressions as indicated by [23]. When multiple probes
mapped the same gene, the mean of the probes was taken
from a particular dataset, and the probes that began with
“AFFX” were deleted, as there were no associated genes for
these probes.The training and testing datasets were processed
separately to ensure the independency of the testing datasets.
The detailed information of the training and testing datasets
is shown in Table 1.
2.2. Integrated Training Dataset. In this study, the task is
to build a computational model that can accurately predict
breast cancer patients with good prognosis or poor prognosis.
As indicated by Sun et al. [24], larger-scale computational
studies with more patient samples are required to best per-
form breast cancer prognosis given all available information.
To achieve this goal, we integrate various training datasets
by performing the following steps. First, the samples with
missing gene expressions were deleted to remove any bias
associated with them. Next, for any dataset d, the gene
expression values were normalized between 0 and 1, by using
(1) [24]
𝑒
(𝑔)
𝑖
=
𝑒
(𝑔)
𝑖
− 𝑒
min(𝑔)
𝑒
max(𝑔)
− 𝑒
min(𝑔) ,
(1)
where 𝑒(𝑔)
𝑖
expresses the 𝑔th feature gene expression value for
the 𝑖th sample and 𝑒min(𝑔) and 𝑒max(𝑔) represent the𝑔th feature
minimum and maximum gene expression value. This nor-
malization mapped gene expression value is generated from
different protocols into a uniform framework so the impact of
the different protocols on the data integration can be reduced.
Compared with the original data, the normalized gene
expressions did not show any significant differences among
study objects.
Further, a common list of genes from the distinctmicroar-
ray platforms was extracted by cross-referencing each probe
annotation in the microarray dataset. The cross-referencing
of microarray gene expression data was done by the UniGene
database [25]. To increase the dataset size (i.e., to overcome
the “curse of dimensionality issue”), the list of common genes
(i.e., 11,837 genes) from thirteen training microarray gene
expression datasets was then directly integrated to have three
unique Affymetrix platforms.This enables the gene signature
to be independent of microarray datasets or their platform
types. The integrated training dataset consists of GSE6532,
GSE3494, GSE2990, GSE4922, GSE 31519, GSE 19615, GSE
1456, GSE 2603, GSE 2034, GSE 5327, GSE 12276, GSE 11121,
and E-TABM-158.This makes a total of 13 datasets with 2,692
samples.
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3. Integrated Prognosis Risk
Estimation Algorithm
The integrated dataset is used to construct the virtual chro-
mosome (VC) in order to extract the prognostic gene signa-
ture. Furthermore, the clinical variables and our prognostic
gene signature are incorporated in a multivariate logistic
regression model which formed the risk score formula for
predicting the prognosis outcome of breast cancer patients.
Details of our IPRE algorithm are presented in the following
sections.
3.1. Virtual Chromosome (VC). We introduced a term called
virtual chromosome (VC) which evaluates the prognos-
tic score (observes significant differentially expressed gene
expressions between two prognosis groups) of each gene in
order to extract the prognosis based gene signature. A virtual
chromosome consists of two components, that is, correla-
tion factor (𝛼) and penalized factor (𝛽) (as shown in (5)).
The prime concept of VC is to transform these two com-
ponents into a combined value that reflects the prognostic
significance of the genes.
In particular, 𝛼 assesses the prognostic significance of
each gene across all the samples in the integrated dataset.
From the integrated dataset, we formed two groups. Group
1 had a metastasis or recurrence rate less than or equal to 5
years (most common point used in the literature) and Group
2 had a metastasis or recurrence rate greater than 5 years.
The gene expression value of 0.5 (the middle value) was
chosen as the probability measure, where the gene expres-
sions less than 0.5 and greater than (or equal to) 0.5 were
regarded as underexpressed and overexpressed gene expres-
sions, respectively. To evaluate 𝛼 for any gene, we first define
the correlation-coefficient (cc) between metastasis or recur-
rence rate and gene expression as follows:
cc (TTP
𝑖
, 𝑒
𝑔
𝑖
)
=
{
{
{
{
{
1; if (TTP
𝑖
≤ 5, 𝑒
𝑔
𝑖
< 0.5)
OR (TTP
𝑖
> 5, 𝑒
𝑔
𝑖
≥ 0.5)
−1; Otherwise,
(2)
where TTP
𝑖
defines the time to progression (i.e., metastasis
or recurrence rate (in years)) for 𝑖th sample, 𝑒𝑔
𝑖
defines gene
expression of gene 𝑔 in the 𝑖th sample, and cc(TTP
𝑖
, 𝑒
𝑔
𝑖
)
defines the correlation-coefficient between TTP
𝑖
and 𝑒𝑔
𝑖
.
Therefore, the correlation-factor (𝛼) for any gene 𝑔 can then
be evaluated as
𝛼
(𝑔)
=
1
𝑁
(𝑝 − 𝑞) , (3)
where 𝑁 defines the total number of samples in a dataset,
𝑝 defines the total number of samples from the two groups
that have the correlation-coefficient equaling 1, and 𝑞 defines
the total number of samples from the two groups that have
the correlation-coefficient equaling −1. Here, 𝛼 evaluates the
difference between two prognostic groups from a microlevel,
and the higher the 𝛼 of a gene, the higher chance of being
prognostically associated with breast cancer, and vice versa.
However, 𝛼 considered the microlevel dichotomized gene
expression with dichotomized TTP (i.e., with two prognostic
groups). Therefore, in order to reflect the actual difference
between two prognostic groups, we used 𝛽 (see (4)) that
incorporated an actual gene expression level from a macro
point of view.
Specifically, the penalized factor (𝛽) penalizes each gene
across all samples depending on the size difference between
the two groups (i.e., Group 1 and Group 2, as mentioned
above). For any gene 𝑔, we first evaluated the mean of each
group based on the actual gene expression level, and the
higher the difference between the mean of the two groups
was, the lesser it was penalized, and vice versa. Mathemati-
cally, 𝛽 for any gene 𝑔 can then be evaluated as
𝛽
(𝑔)
= 1−
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
(∑
𝐺
1
𝑖=1
𝑒
(𝑔)
𝑖
)
𝐺
1
−
(∑
𝐺
2
𝑗=1
𝑒
(𝑔)
𝑗
)
𝐺
2
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
󵄨
, (4)
where 𝐺
1
and 𝐺
2
define the total number of samples that
belong to the Group 1 and Group 2, respectively, and 𝑒(𝑔)
𝑖
and
𝑒
(𝑔)
𝑗
define the gene expression of gene 𝑔 in the 𝑖th and 𝑗th
sample, respectively. Here, 𝛽 evaluates the actual difference
between two prognostic groups from a macrolevel, and the
higher the 𝛽 of a gene is, the less chance the gene will be
selected in our prognostic gene signature, and vice versa.
Therefore, to assess the overall prognostic significance of
any gene𝑔 in the integrated dataset, theirVC can be evaluated
as the weighted combination of 𝛼 and 𝛽; that is,
VC(𝑔) = (𝜏
1
∗ 𝛼
(𝑔)
) + (𝜏
2
∗ 𝛽
(𝑔)
) , (5)
where𝛼(𝑔) and𝛽(𝑔) represent correlation factor and penalized
factor for gene 𝑔, respectively, and 𝜏
1
and 𝜏
2
represent
the weight associated with 𝛼 and 𝛽, respectively. For the
current setting, we assigned 𝜏
1
equals 1 and 𝜏
2
equals −1.0011,
and these were chosen from our experimental analysis (i.e.,
by performing multivariate logistic regression analysis (see
Section 3.3 for details)). The higher the VC score of a gene,
the more chance of being selected in our prognostic gene
signature, and vice versa. Finally, to extract the set of robust
genes based on their VC score, we constructed the robust
virtual chromosome.
3.2. Robust Virtual Chromosome. Our aim was to identify a
set of robust genes with high VC scores in order to form our
prognostic gene signature. For this purpose, we performed
the following operations.
(i) First, we sorted the VC in descending order and then
assigned a rank based on their VC values. The top
gene shows the highest rank based on the highest
VC value and the bottom gene shows the lowest rank
based on the lowest VC value; that is,
Sorted VC = {VC
𝑛
} ; 1 ≤ 𝑛 ≤ 𝜑
s.t VC
1
≥ VC
2
≥ VC
3
≥ ⋅ ⋅ ⋅ ≥ VC
𝜑
,
(6)
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Algorithm HR 95% CI P value HR plot
IPRE 0.235 0.138 to 0.401 5.32e − 09
RAND 0.326 0.191 to 0.557 1.59e − 05
ITI 0.349 0.215 to 0.597 5.07e − 05
70g 0.733 0.428 to 1.259 0.261
76g 0.374 0.183 to 0.690 1.89e − 03
GGI 0.356 0.221 to 0.642 4.49e − 04
LRT 0.386 0.199 to 0.749 4.96e − 03
IGS 0.918 0.533 to 1.580 0.759
21 g 0.299 0.088 to 0.908 0.023
DMFS association: Strong Weak
0.1 0.2 0.5 1 2 5
Figure 1: Hazard ratios for comparison of distant metastasis free survival (DMFS) association of IPRE and other algorithms in the Desmedt
dataset. Here, HR stands for hazard ratio and 95% CI represents 95% confidence intervals. The lesser the HR is, the stronger the survival
association of the algorithm is. Many existing published gene signatures and random gene signatures of identical size are not better outcome
predictors than IPRE.
Increases
Maximum
Decreases
VC1 VC2 VC3 VC𝜑· · ·
VC1 + VC2
√2
VC1 + VC2 + VC3
√3
VC1 + VC2 + VC3 + · · · + VC𝜑
√𝜑
...
Figure 2: Robustness score overview. Here, VC
𝜑
represents the VC for any 𝜑th ranked gene. The robustness score in the list increases first
until a certain point and then achieves a maximum robustness score, and thereafter, begins to decrease.
where VC
𝑛
defines the VC value for any gene that has
been given 𝑛th rank and 𝜑 defines the total number of
genes in the integrated dataset. In the sorted VC list,
the top genes through to the bottom genes reflect the
highly associated to the least associated differentially
expressed genes in regards to breast cancer prognosis.
(ii) Next, while moving down the sorted VC list, we
defined the robustness score (𝑅) in order to identify
how far the genes can be selected to form our prog-
nostic gene signature. In other words, the robustness
score for any set of genes defines the weighted sum of
the genes VC with their weight which is evaluated as
an inverse square root of the number of genes [26].
Specifically, the robustness score for any 𝑚th rank
gene (𝑔
𝑚
) is
𝑅
(𝑔
𝑚
)
= 𝑅
𝑚
=
1
√𝑚
(
𝑚
∑
𝑛=1
VC
𝑛
) . (7)
The robustness score in the VC list first increases as
it moves down, and then at a certain point achieves
a maximum robustness score and thereafter starts
decreasing. Figure 2 illustrates the robustness score
mechanism. The prime reason to generate a robust-
ness score for the sorted VC list is to identify a set of
top ranked robust genes thatmaximise the robustness
score.Therefore, by using (7), the robustness score for
each gene in the sorted VC list can be evaluated.
(iii) Finally, to extract the robust genes, we identified the
robustness score that is the maximum in the sorted
VC list. Therefore, the top gene until the gene whose
robustness score is maximum formed our prognostic
gene signature; that is,
𝑅max = max
1≤𝑚≤𝜑
𝑅
𝑚
,
Our Prognostic Gene Signature = {𝑔
𝑛
}
s.t 𝑅(𝑔𝑛) = 𝑅
𝑛
; 𝑅
1
≤ 𝑅
𝑛
≤ 𝑅max.
(8)
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Table 2: Variables used in our multivariate logistic regression
model.
Variable Characteristics Code
𝑋1 Tumour grade
(I-II)
(III)
0
1
𝑋2 Tumour size (cm)
(<2)
(2-3)
(≥4)
0
0.55
1
𝑋3 ER (estrogen receptor)
(−)
(+)
−1
1
𝑋4 PR (progesterone receptor)
(−)
(+)
−1
1
𝑋5
HER2 (human epidermal
growth factor receptor 2)
(−)
(+)
−1
1
𝑋6
mScore (mean of our
prognostic gene signature) (0 to 1) NA
3.3. Risk Score Estimation Using the Logistic RegressionModel.
The multivariate logistic regression model was constructed
(that used clinical data and microarray data) in an attempt to
robustly discover the predictors of prognosis risk for breast
cancer patients.
For each sample in the integrated dataset, we first gen-
erated the gene expression mean of our prognostic gene
signature and referred to this as the mScore. Next, for patient
samples with a missing ER or PR status, the dichotomized ER
gene (ESR1) and PR gene (PgR) mRNA (positive and neg-
ative) values were considered. We used the following influ-
ential variables in our multivariate logistic regression model,
as mentioned in Table 2.
By using the variables shown in Table 2, the multivariate
logistic regressionmodelwas constructed using the backward
selection approach to form the risk score (RS) formula. The
standard way to represent multivariate logistic regression
equation is
Logit (𝑃) = 𝛽
0
+ 𝛽
1
𝑋
1
+ 𝛽
2
𝑋
2
+ ⋅ ⋅ ⋅ + 𝛽
𝑛
𝑋
𝑛
, (9)
where Logit(𝑃) = ln[𝑃/(1−𝑃)],𝑃 is the estimated probability
of breast cancer prognosis, 𝛽
0
defines the constant, and 𝛽
𝑛
defines the regression coefficient for the 𝑛th variable (i.e.,𝑋
𝑛
variable). Here, 𝑋
𝑛
is a promoting factor if 𝛽
𝑛
> 0, and 𝑋
𝑛
is a suppressing factor if 𝛽
𝑛
< 0. A model with 𝑋
𝑛
that has
a 𝑃 value less than or equal to 0.05 was considered to be
statistically significant.
The receiver operating characteristic (ROC) curves were
used to assess the performance of the prediction model and
determined an optimal cut-off point of 𝜖 that gives maximum
sensitivity and specificity. Therefore, a sample can be clas-
sified as a good/poor prognosis if their RS is lesser/greater
than the chosen cut-off point of 𝜖 from (9). The full
algorithm workflow is shown in Figure 3.
4. Results and Discussion
We conducted experiments on the integrated dataset of
2,692 samples (see Section 2.2). The samples with repetitions
or a missing metastasis or recurrence rate were excluded.
2,268 samples remained, consisting of 897 poor prognosis
breast cancer patients (metastasis or recurrence rate within
five years) and 1,371 good prognosis breast cancer patients
(metastasis or recurrence rate with more than five years). We
named this integrated dataset the 2,268 dataset for illustrative
purposes during our experiment.
Since the 2,268 dataset contained unequal numbers of
samples in two prognosis groups, this may have caused
algorithm bias towards the group with the higher number of
samples.Therefore, to reduce the bias in the 2,268 dataset, we
balanced both good and poor prognosis patient samples, that
is, 897 poor prognosis breast cancer patients and 897 good
prognosis breast cancer patients, with a total of 1,794 samples.
We called this integrated dataset the 1,794 dataset for illustra-
tive purposes during our experiment.
By applying our IPRE algorithm on the 1,794 dataset, we
identified 79 breast cancer prognostic genes (log-rank test,
value < 2𝑒 − 16) that formed our prognostic gene signa-
ture (see supplementary Table S1 in Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2014/459203).
The mScore (mean score of the gene signature) was
then generated for each sample in the 1,794 dataset (see
Section 3.3).
The “survival” package of the R-project (R Development
Core Team, 2008) has been used to generate multivariate
logistic regression analysis on the 1,794 dataset with variables
such as ER, PR, HER2, tumour size, tumour grade, and
mScore. As discussed earlier, we considered and selected
variables that had a 𝑃 ≤ 0.05 from our multivariate model
and further used the risk score estimation to classify a sample
as either a good or poor prognosis based on the score. Table 3
lists the results of the variables (asmentioned in Table 2) from
our multivariate analysis.
FromTable 3, the tumour grade and theHER2 status vari-
able were not selected as their 𝑃 > 0.05. Therefore, tumour
size, ER, PR, and the mScore were selected (being statistically
significant) in our multivariate logistic regressionmodel, and
the risk score (RS) formula generated from our model used
for predicting the prognosis of breast cancer patients was
represented as
RS = −0.99475 − 0.34534𝑋
2
− 0.19854𝑋
3
− 0.21123𝑋
4
− 1.13115𝑋
6
.
(10)
With (10), the risk score can be estimated for any sample
that can classify breast cancer patients into either a good or
poor prognosis using the chosen cut-off point of 𝜖. From our
experiments (see Section 4.1), we identified 𝜖 equals −1.480,
which determines a sample to be a poor prognosis if their RS
is greater than or equal to −1.480. However, a sample can be
classified as a good prognosis if their RS is less than −1.480;
that is,
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Figure 3: IPRE algorithm workflow.
Table 3: Multivariate analysis of the variables in the 1,794 dataset.
Variable Characteristics 𝛽 𝑧 SE 𝑃 Selected
𝑋1 Grade −0.06176 −0.674 0.09163 0.50 No
𝑋2 Size −0.34534 −3.029 0.11401 0.002 Yes
𝑋3 ER −0.19854 −4.441 0.04471 8.95𝐸 − 06 Yes
𝑋4 PR −0.21123 −4.356 0.04849 1.33𝐸 − 05 Yes
𝑋5 HER2 0.08819 1.761 0.05007 0.08 No
𝑋6 mScore −1.13115 −12.918 0.08757 2.00𝐸 − 16 Yes
Constant −0.99475
If RS ≥ −1.480,
then it is a poor prognosis (or high risk patients to
breast cancer metastasis/recurrence).
Else, If RS < −1.480,
then it is a good prognosis (or low risk patients to
breast cancer metastasis/recurrence).
The classification results on the 1,794 dataset, the 2,268
dataset, and the two testing datasets, in addition to a compar-
ison with other popular existing prognosis based algorithms,
are detailed in the following subsections.
4.1. Classification Results on Integrated Training Datasets.
We first performed experiments on an integrated training
dataset, that is, 2,268 dataset, and then on the 1,794 dataset.
The experiments were initially performed on a constructed
risk score formula (10) with different cut-off points in order to
choose the robust cut-off point that can characterize the two
prognosis breast cancer patient groups with high accuracy,
sensitivity, and specificity. We define sensitivity as the ability
of the algorithm to identify the poor prognosis patients as
poor-prognosis, specificity as the ability of the algorithm to
identify the good prognosis patients as good-prognosis, and
accuracy as the ability of the algorithm to accurately identify
the patients as either good or poor prognosis patients. Our
aim was not just to achieve high accuracy while ignoring
sensitivity or specificity, but to achieve high sensitivity,
specificity, and accuracy. It should be noted that we are more
interested in achieving high specificity in order to spare the
good prognosis patients from aggressive treatments. At the
same time, we are interested in achieving high sensitivity in
order to guide poor prognosis patients about the advanced
treatment options available to them.
The supplementary Table S2 shows the classification
results of our IPRE algorithm with different cut-off points in
the 1,794 dataset and 2,268 dataset, respectively. The supple-
mentary Table S2 shows that a cut-off point of−1.480 (in both
the datasets) achieves high F-value, sensitivity, specificity,
and accuracy, amongst others, and therefore −1.480 is chosen
as a cut-off point in our risk score formula. Specifically, on
the 1,794 dataset, the IPRE algorithm achieves 73% F-value,
77% accuracy, 63% sensitivity, and 91% specificity. On the
other hand, for the 2,268 dataset, the IPRE algorithm achieves
59% F-value, 66% accuracy, 60% sensitivity, and 71% speci-
ficity. These results are reported in supplementary Table S2
(highlighted as bold) with their boxplots shown in supple-
mentary Figure S1. Clearly, the 1,794 dataset that has equal
proportions of the two prognosis groups shows much better
results than the 2,268 dataset.
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Figure 4: ROC curves of the IPRE algorithm in the 1,794 dataset and
the 2,268 dataset. Clearly, this validates the 1,794 dataset as better
compared to the 2,268 dataset.
The overall performance of the model was assessed by
drawing receiver operating characteristic (ROC) curve at
different thresholds and by evaluating the area under the
ROC curve (AUC). The larger the area under the ROC curve
of an algorithm, the more effective the algorithm is. A model
with an AUC of 0.5 is similar to flipping a coin. The ROC
curve of an IPRE algorithm in the 1,794 dataset and the 2,268
dataset is shown in Figure 4.
The performance of the IPRE algorithm is good in the
1,794 dataset with an AUC of 0.770, whereas the algorithm
performs average on the 2,268 dataset with an AUC of 0.688.
This demonstrates that the 1,794 dataset was less biased than
the 2,268 dataset, and therefore, was used to extract our prog-
nostic gene signature and risk score formula (10) to classify
the good and poor prognosis patient groups in the testing
datasets.
Further, we compared our IPRE algorithm (that consists
of clinical variables and gene signature) with IPRE (G) (that
consists of gene signature) and IPRE (C) (that consists of
clinical variables) on the 1,794 dataset and 2,268 dataset,
respectively. The operations were similar to IPRE for the
training and the construction of the risk-score formula for
IPRE (G) and the IPRE (C), respectively. Figure 5 shows
the classification results of the IPRE, IPRE (G), and IPRE
(C) algorithm, which clearly show the IPRE algorithm that
consists of both genetic and clinical components outperforms
IPRE (G), that consists of a genetic component only, and IPRE
(C), that consists of a clinical component only. Also, IPRE
(G) shows better results than IPRE (C), which shows the
effectiveness of our gene signature.
4.2. Classification Results on Testing Datasets. To assess the
performance of our model with a chosen cut-off point of
−1.480 (see (10)) constructed with the IPRE algorithm, two
testing datasets were used, that is, (a) the Desmedt dataset
(GSE7390) [22] and (b) the Vijver dataset [3]. Compar-
isons with seven other existing prognosis based algorithms
along with IPRE (G) and IPRE (C) were also performed
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Figure 5: Classification results of the IPRE (C), IPRE (G), and
IPRE algorithm on the 1,794 and 2,268 dataset. Here, ACC defines
accuracy, SE defines sensitivity, and SP defines specificity.
to demonstrate that the IPRE algorithm was more effective
and outperformed other existing algorithms. The algorithms
are the 70-gene signature [3], the 21-gene signature [4],
the 76-gene signature [5], the genomic grade index (GGI)
[6], the invasiveness gene signature (IGS) [8], the 112-gene
signature [9], and the interactome-transcriptome integration
(ITI) [16]. Table 4 and Figure 6 show the classification results
of the IPRE algorithm along with IPRE (G), IPRE (C), and
seven other existing algorithms in the testing dataset of the
Desmedt and the Vijver, respectively. Furthermore, the IPRE
algorithm boxplots for the Desmedt and the Vijver dataset
are shown in Figure 8. This clearly illustrates the separation
between the two prognosis groups.
Table 4 and Figure 6 show that the IPRE and IPRE
(G) algorithms achieved superior results compared to IPRE
(C) and other existing popular prognosis based algorithms.
Specifically, on the Desmedt dataset, the IPRE and IPRE (G)
algorithms were able to achieve a prognosis classification
accuracy of 82% (specificity of 88%) and 77% (specificity of
84%), respectively, which was significantly higher than the
classification accuracies of IPRE (C), that is, 60% (specificity
of 68%), and other existing algorithms, that is, 60% (speci-
ficity of 57%) for GGI, 40% (specificity of 28%) for 70 g, 54%
(specificity of 53%) for 76 g, 52% (specificity of 42%) for 112 g,
58% (specificity of 59%) for IGS, 33% (specificity of 16%)
for 21 g, and 72% (specificity of 82%) for ITI. Similar results
were achieved from the Vijver dataset which shows the IPRE
and IPRE (G) algorithms were able to achieve a prognosis
classification accuracy of 87% (specificity of 95%) and 80%
(specificity of 89%), respectively. This was much higher than
the classification accuracies of IPRE (C) and other existing
algorithms (see Table 4). From the two testing datasets, the
IPRE algorithmachieved the highest accuracy andperformed
better than any of the others, including IPRE (G), IPRE (C),
and other existing algorithms. It should be noted that if
comparing existing algorithms in the Desmedt dataset, ITI
showed the second best results (in terms of accuracy) and
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Table 4: Prognosis based classification results of the IPRE, IPRE (G), IPRE (C), and seven other existing algorithms in the testing dataset of
(a) the Desmedt and (b) the Vijver.
Algorithm 𝑁 TN FP TP FN SE (95% CI) SP (95% CI) ACC (95% CI)
(a) Desmedt dataset
GGI 190 86 66 28 10 0.737 (0.60 to 0.88) 0.566 (0.49 to 0.64) 0.600 (0.53 to 0.67)
70 g 190 42 110 34 4 0.895 (0.80 to 0.99) 0.276 (0.21 to 0.35) 0.400 (0.33 to 0.47)
76 g 190 80 72 23 15 0.605 (0.45 to 0.76) 0.526 (0.45 to 0.61) 0.542 (0.47 to 0.61)
112 g 190 64 88 34 4 0.895 (0.80 to 0.99) 0.421 (0.34 to 0.50) 0.516 (0.45 to 0.59)
IGS 190 90 62 21 17 0.553 (0.39 to 0.71) 0.592 (0.51 to 0.67) 0.584 (0.51 to 0.65)
21 g 190 25 127 38 0 1 (1.00 to 1.00) 0.164 (0.11 to 0.22) 0.332 (0.27 to 0.40)
ITI 190 124 28 12 26 0.316 (0.17 to 0.46) 0.816 (0.75 to 0.88) 0.716 (0.65 to 0.78)
IPRE (C) 190 104 48 9 29 0.237 (0.10 to 0.37) 0.684 (0.61 to 0.76) 0.595 (0.53 to 0.67)
IPRE (G) 190 128 24 19 19 0.500 (0.34 to 0.66) 0.842 (0.78 to 0.90) 0.774 (0.71 to 0.83)
IPRE 190 133 19 23 15 0.605 (0.45 to 0.76) 0.875 (0.82 to 0.93) 0.821 (0.77 to 0.88)
(b) Vijver dataset
GGI 150 68 38 28 16 0.636 (0.49 to 0.78) 0.642 (0.55 to 0.73) 0.640 (0.56 to 0.72)
70 g 150 51 55 39 5 0.886 (0.79 to 0.98) 0.481 (0.39 to 0.58) 0.600 (0.52 to 0.68)
76 g 150 65 41 28 16 0.636 (0.49 to 0.78) 0.613 (0.52 to 0.71) 0.620 (0.54 to 0.70)
112 g 150 42 64 33 11 0.750 (0.62 to 0.88) 0.396 (0.30 to 0.49) 0.500 (0.42 to 0.58)
IGS 150 38 68 40 4 0.909 (0.82 to 0.99) 0.358 (0.27 to 0.45) 0.520 (0.44 to 0.60)
21 g 150 2 104 44 0 1 (1.00 to 1.00) 0.019 (−0.01 to 0.04) 0.307 (0.23 to 0.38)
ITI 150 78 28 10 34 0.227 (0.10 to 0.35) 0.736 (0.65 to 0.82) 0.587 (0.51 to 0.67)
IPRE (C) 150 76 30 8 36 0.182 (0.07 to 0.30) 0.717 (0.63 to 0.80) 0.560 (0.48 to 0.64)
IPRE (G) 150 94 12 25 19 0.568 (0.42 to 0.71) 0.887 (0.83 to 0.95) 0.793 (0.73 to 0.86)
IPRE 150 101 5 29 15 0.659 (0.52 to 0.80) 0.953 (0.91 to 0.99) 0.867 (0.81 to 0.92)
Here, N defines the total number of samples, TP defines true positive, TN defines true negative, FP defines false positive, FN defines false negative, SE defines
sensitivity, SP defines specificity, ACC defines accuracy, and 95% CI defines 95% confidence intervals. Due to space restrictions, we represent the genomic
grade index as GGI, 70-gene signature as 70 g, 76-gene signature as 76 g, 112-gene signature as 112 g, invasiveness gene signature as IGS, 21-gene signature as
21 g, and interactome-transcriptome integration as ITI. From the table, the IPRE algorithm achieved superior performance amongst others (as highlighted in
bold) in the Desmedt dataset and the Vijver dataset.
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Figure 6: Classification results of IPRE, IPRE (G), IPRE (C), and seven other existing algorithms on the Desmedt and Vijver dataset. Here,
SE defines sensitivity, SP defines specificity, and ACC defines accuracy.
GGI ranked third. On the other hand, in the Vijver dataset,
GGI ranked second and ITI ranked fifth. This points to the
fact that the classification accuracy of existing algorithms
heavily depends on their choice of training dataset.Therefore,
it can be true to say that existing algorithms do not show
consistent performances across distinct microarray datasets
as these algorithms are biased towards the datasets used
for generating gene signatures. However, by increasing the
training compendia to a large number of samples with
multiple microarray platforms, the algorithm’s dependency
on the datasets or microarray platforms can be greatly
reduced. This was demonstrated by the IPRE algorithm as
we incorporated multiple training datasets with a very large
number of samples across multiple microarray platforms.
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prognosis groups, the 𝑦-axis represents the risk scores, and the dotted horizontal line represents our chosen cut-off point, that is, −1.480. It
can be clearly seen that the two prognosis groups are separated in both datasets.
Therefore, these results concluded that the IPRE algorithm
was stable and robust against any testing dataset or their
microarray platform in order to categorise good prognosis
(low risk) versus poor prognosis (high risk) breast cancer
patients.
Further, to fairly evaluate and compare the performance
of existing algorithms by removing any differences that
come with clinical variables or their gene signatures, the
logistic regression model was constructed (that used clinical
variables and a gene signature) for each existing algorithm
in a similar way as constructed for IPRE (see Section 3.3).
For simplicity, we still denote the existing algorithms as
IGS, 21 g, 112 g, 70 g, 76 g, GGI, and ITI. Figure 7 shows
the classification performance of IPRE and other existing
algorithms constructed using the logistic regression model
with considered clinical variables and their respective gene
signature, and also shows that the IPRE algorithm achieved
higher specificity and accuracy that outperformed other
existing algorithms. For each of the existing algorithms, these
experiments concluded that integrating clinical variables and
gene signatures (see Figure 7) showed better classification
performances than considering only gene signatures (see
Figure 6). Furthermore, these experiments conducted using
different angles showed the effectiveness of the proposed
algorithm in classifying the two prognosis groups.
Venet et al. [35] compared 47 breast cancer gene signa-
tures to the signatures made by random genes and claimed
thatmost randomgene expression signatures are significantly
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represents the median 𝑃 value generated from the random gene
signatures.
associated with the breast cancer outcome. Their study
showed that almost 60% of existing gene signatures were not
significantly better outcome predictors than the random gene
signatures that contain 1,000 gene signatures of identical size,
and nearly 23% of them were worse predictors. Therefore, to
compare the IPRE algorithm against random gene signatures,
we constructed 1,000 random gene signatures of identical
size. For fair evaluationwith the IPRE algorithm, we incorpo-
rated the clinical variables with the random gene signatures
and called it RAND.
Figure 9 reveals that the IPRE algorithm showed a sig-
nificantly stronger association with distant metastasis free
survival (DMFS) outcome than the median of the random
gene signatures (RAND) in the Desmedt dataset and the
Vijver dataset, respectively. The classification results of the
RAND and IPRE algorithms in the Desmedt dataset and the
Vijver dataset, as shown in Table 5, clearly show that the IPRE
algorithm significantly outperformed RAND.
To get the overall picture of the performance compar-
ison of IPRE and other existing algorithms, we calculated
hazard ratios using all combinations of DMFS end-points
and cohorts in the Desmedt dataset, as shown in Figure 1
with their related survival analysis discussed below (see
Figure 10). Our analysis concludes that the IPRE algorithm
was a significantly better outcome predictor than random
gene signatures of an identical size. However, the random
gene signatures showed significantly better outcomes than
other published gene signatures used in our study. These
results further validate the findings of Venet et al. [35] who
suggest most existing gene signatures are not significantly
better outcome predictors than the random gene signatures
of identical size.
Next, a Kaplan-Meier survival analysis is performed on
the Desmedt dataset by using the “survival” package of the R-
project (R Development Core Team, 2008). Figure 10 shows
the survival curves of the IPRE algorithm and seven other
existing algorithms using the DMFS rate. The Log-rank sta-
tistical test gave a𝑃 value of 5.32𝑒−09 for the IPRE algorithm,
which was statistically significant (i.e., value ≤ 0.05), and
indicated the best separation between the two prognosis
groups (i.e., good prognosis or low risk to distant metastasis,
and poor prognosis or high risk to distant metastasis) as
compared with other existing algorithms. It should be noted
that the 70 g and IGS algorithms were incapable of separating
patients into significant prognostic groups (𝑃 value > 0.05).
These results supported our previous conclusions that the
IPRE algorithm was robust enough to separate patients into
two significant prognosis groups.
4.3. Our Prognostic Gene Signature Stability with Existing
Gene Signatures. We performed stability analysis for assess-
ing the overlap between existing gene signatures and our
prognostic gene signature. Table 6 shows the number of over-
lapped genes from our prognostic gene signature compared
with other existing signatures.
Our prognostic gene signature shows the overlap with
existing gene signatureswithin the range of 1–21%.Wediscov-
ered that gene signatures extracted from themultiple training
datasets, such as ITI, performed better and showed greater
overlap with our gene signature, that is, 21%.This overlap was
significantly greater compared to other gene signatures gen-
erated from a lower number of training samples.This demon-
strates the effectiveness of incorporating a larger number of
patient samples in a training dataset withmultiplemicroarray
platforms to enhance the performance of the algorithm
across a wide range of testing datasets.
4.4. Biological Analysis of Our Prognostic Gene Signature. The
biological analysis of our prognostic gene signature was per-
formed using the gene ontology (GO) analysis and pathway
analysis. For each gene in our prognostic gene signature,
GO analysis was performed using the enriched biological
process GO terms [36]. The pathway analysis was performed
using the KEGG pathways [37].
First, we input genes in our prognostic gene signature
into the program called Database for Annotation, Visualiza-
tion, and Integrated Discovery (DAVID) [33]. DAVID then
produced the enriched biological process GO terms and the
associated KEGG pathways with their 𝑃 values computed
using hypergeometric distribution.This program was helpful
to identify the significantGO terms andKEGGpathways.The
supplementary Tables S3 and S4 represent the enriched GO
terms and the enriched KEGG pathways for our prognostic
gene signature, respectively.
From supplementary Table S3, it can be seen that several
enriched GO terms are associated with the processes that
were seen to be disrupted in the cancers, such as regulation
of apoptosis, regulation of transcription, cell proliferation,
positive regulation of cell activation, and positive regulation
of immune response, besides many others. Furthermore, the
supplementary Table S4 shows that the pathways of our
prognostic gene signature were related to the cancers, such
as apoptosis, cell cycle, integrin signalling pathway, T cell
activation, ATM signalling, and pathways in cancer. These
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Figure 10: Kaplan-Meier survival graphs for good and poor prognosis groups in the Desmedt dataset for the IPRE algorithm and seven other
existing algorithms. A log-rank test was performed to assess the 𝑃 value and to signify that the lower the 𝑃 value, the better the separation
between the two prognosis groups. From this figure, the IPRE algorithm was able to achieve the lowest 𝑃 value and perform the best at
separating the two prognosis groups.
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Table 5: Prognosis based classification results of the RAND and IPRE algorithms in the testing dataset of (a) the Desmedt and (b) the Vijver.
Algorithm 𝑁 TN FP TP FN SE (95% CI) SP (95% CI) ACC (95% CI)
(a) Desmedt dataset RAND 190 128 24 23 15 0.605 (0.45 to 0.76) 0.842 (0.78 to 0.90) 0.795 (0.74 to 0.85)
IPRE 190 133 19 23 15 0.605 (0.45 to 0.76) 0.875 (0.82 to 0.93) 0.821 (0.77 to 0.88)
(b) Vijver dataset RAND 150 91 15 26 16 0.619 (0.47 to 0.77) 0.858 (0.79 to 0.92) 0.791 (0.73 to 0.86)
IPRE 150 101 5 29 15 0.659 (0.52 to 0.80) 0.953 (0.91 to 0.99) 0.867 (0.81 to 0.92)
Table 6: The number (percentage) of genes in our prognostic gene
signature that matches existing gene signatures.
Existing
gene
signatures
Matched genes of our
prognostic gene signature
(in number (percentage))
Bar representing
matched genes
ITI 16 (21%)
76 g 3 (4%)
70 g 2 (3%)
LRT 2 (3%)
IGS 1 (1.3%)
GGI 0
21 g 0
The last column represents the bar graph of our matched genes (in
percentage) with other gene signatures. Here, the ITI gene signature shows
the maximum overlap (21%) amongst other representative gene signatures.
results demonstrate that our prognostic gene signature con-
sists of biologically significant genes that are biologically
associated with the cancers. The supplementary Figure S2
further illustrates the biological meaning of our prognostic
gene signature by showing the KEGG cell cycle pathway and
the genes in our gene signature (as highlighted in red) that
appear in this pathway. It was observed thatmany genes in our
prognostic gene signaturewere associatedwith theKEGGcell
cycle pathway.
We also observed that various genes in our prognostic
gene signature were previously recognised as oncogenes,
such as, CD74, GATA3, CD24, and C1S, whose altered
expression patterns were associated with different prognosis
states or with various types of cancers [38–41]. However,
for other genes not previously reported as oncogenes, they
may be innovative oncogenes that promote breast cancer or
its aggressiveness. These facts conclude that our prognostic
gene signature is biologically meaningful and relates to breast
cancer prognosis.
5. Conclusion
We proposed a prognosis based classification algorithm to
categorize breast cancer patients as high versus low risk. We
developed a virtual chromosome to extract our prognostic
gene signature that consists of 79 differentially expressed
genes. The current study particularly focused on achieving
high specificity, at the same time as achieving high sensitivity.
For this, a multivariate logistic regression model was then
used to correlate the microarray data (our prognostic gene
signature) and clinical data (tumour size, ER, PR) to generate
the risk score estimation formula. A −1.480 cut-off point was
chosen to distinguish two prognosis groups of breast cancer
patients.
We formed two integrated training datasets, that is,
the 1,794 dataset and the 2,268 dataset, which consisted of
multiple training datasets with a very large number of patient
samples and multiple microarray platforms so the training
size was large enough to reduce any bias associated with
training datasets of a small size and to lessen the dependency
of the algorithm on any particular training dataset. From our
experiments, we concluded the integrated training dataset
(i.e., 1,794 dataset) with equal number of good and poor
prognosis patient samples whichwas less biased and achieved
superior performance compared to the integrated training
dataset (i.e., 2,268 dataset) with unequal numbers of good and
poor prognosis patient samples.
Unlike other algorithms, we observed that the classi-
fication performance of our IPRE algorithm on multiple
testing datasets was consistently good, suggesting that the
IPRE algorithm was independent of any testing dataset when
it achieved high classification performance. Using the two
testing datasets (the Desmedt and Vijver dataset), we demon-
strated that the IPRE algorithm achieved its highest classifi-
cation performance by characterizing a high number of good
and poor prognosis breast cancer patients, and it was able
to outperform random gene signatures of identical size and
seven other popular prognosis based classification algorithms
(see Table 4). This concludes that the IPRE algorithm was
robust and effective in classifying the two prognosis groups
on any dataset without depending on any other factor. The
IPRE algorithm based prognostic gene signature was also val-
idated biologically using GO terms and pathway classes; this
shows that the biological meaning of our prognostic gene
signature was significant. These results concluded that the
IPRE algorithm was significant in achieving high specificity
(and also high sensitivity), which was the initial aim of our
study so that low risk patients avoid unnecessary or aggressive
therapies.
The above discussions and results suggest that the pro-
posed algorithm has the potential to guide physicians at the
early decision stage of breast cancer prognosis. Further, a
phase-2 clinical trial would be advisable to categorize the two
prognosis groups of breast cancer using the IPRE algorithm.
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